ATG

Antengene is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class and best-in-class oncology therapies. The company's lead product, XPOVIO (selinexor), is a first-in-class XPO1 inhibitor approved for multiple hematologic malignancies in several Asia-Pacific markets. Antengene's robust pipeline includes 15 assets ranging from early-stage discovery to late-stage clinical trials, targeting novel pathways such as mTOR, CD73, and ERK1/2. With a dual-engine approach of in-licensing and internal R&D, the company aims to address significant unmet medical needs in cancer treatment globally. Antengene is headquartered in Shanghai and is listed on the Hong Kong Stock Exchange.